A Single-Blind, Randomized, Monocentric Phase II Trial to Explore the Safety and Rabies-Neutralizing Activity of Combined Administration of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin Plus Rabies Vaccine in Simulated Rabies Post-Exposure Prophylaxis in Children and Adolescents.

Trial Profile

A Single-Blind, Randomized, Monocentric Phase II Trial to Explore the Safety and Rabies-Neutralizing Activity of Combined Administration of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin Plus Rabies Vaccine in Simulated Rabies Post-Exposure Prophylaxis in Children and Adolescents.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2012

At a glance

  • Drugs Foravirumab; Rabies immune globulin; Rabies vaccine
  • Indications Rabies
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Crucell
  • Most Recent Events

    • 20 Oct 2009 Results have been presented in a Crucell media release.
    • 24 Jun 2009 Status changed from active, no longer recruiting to completed.
    • 27 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top